QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
This work has been published in the journal ‘ACS applied materials and interface’
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
CDSCO to fast-track trials and approval for COVID19 vaccine
Innovative solutions and a deep understanding of the market makes this a unique combination
Startup receives US $ 5 million in first round of funding
Subscribe To Our Newsletter & Stay Updated
